Insider filing report for Changes in Beneficial Ownership
- Schedule 13G & 13D forms are used to report a party's ownership of stock which exceeds 5% of a company's total stock issue.
- Schedule 13G is a shorter version of Schedule 13D with fewer reporting requirements.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| UNITED STATES | ||
SECURITIES AND EXCHANGE COMMISSION | ||
Washington, D.C. 20549 | ||
SCHEDULE 13G | ||
(Rule 13d-102) | ||
INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT | ||
TO RULES 13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED | ||
PURSUANT TO RULE 13d-2(b) | ||
(Amendment No. 1)1 | ||
ESSA Pharma Inc. | ||
(Name of Issuer) | ||
Common Shares, no par value | ||
(Title of Class of Securities) | ||
29668H708 | ||
(CUSIP Number) | ||
December 31, 2021 | ||
(Date of Event Which Requires Filing of this Statement) | ||
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
[ ] Rule 13d-1(b)
[X] Rule 13d-1(c)
[ ] Rule 13d-1(d)
1.The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page. The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act.
CUSIP No. 29668H708
| 1. | NAME OF REPORTING PERSON S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON (VOLUNTARY) Pfizer Inc. 13-5315170 | |||||||||||||
| 2. | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP | (a) [ ] (b) [ ] | ||||||||||||
| 3. | SEC USE ONLY | |||||||||||||
| 4. | CITIZENSHIP OR PLACE OF ORGANIZATION Delaware | |||||||||||||
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH | 5. | SOLE VOTING POWER 1,675,000 | ||||||||||||
| 6. | SHARED VOTING POWER -0- | |||||||||||||
| 7. | SOLE DISPOSITIVE POWER 1,675,000 | |||||||||||||
| 8. | SHARED DISPOSITIVE POWER -0- | |||||||||||||
| 9. | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 1,675,000* | |||||||||||||
| 10. | CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES | [ ] | ||||||||||||
| 11. | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 3.81% * | |||||||||||||
| 12. | TYPE OF REPORTING PERSON CO | |||||||||||||
* Based on 44,015,870 shares of Common Stock outstanding as set forth in the Issuer’s Quarterly Report on Form 10-Q for the quarter ended on December 31, 2021, filed with the SEC on February 3, 2022.
Page 2 of 5
CUSIP No. 29668H708
SCHEDULE 13G
ITEM 1(a) | NAME OF ISSUER: | ||||
ESSA Pharma Inc. | |||||
ITEM 1(b) | ADDRESS OF ISSUER’S PRINCIPAL EXECUTIVE OFFICES: | ||||
Suite 720, 999 West Broadway, Vancouver, British Columbia, Canada V5Z 1K5 | |||||
ITEM 2(a) | NAME OF PERSON FILING: | ||||
Pfizer Inc. | |||||
ITEM 2(b) | ADDRESS OF PRINCIPAL BUSINESS OFFICE: | ||||
235 East 42nd Street, New York, NY 10017 | |||||
ITEM 2(c) | CITIZENSHIP: | ||||
Delaware | |||||
ITEM 2(d) | TITLE OF CLASS OF SECURITIES: | ||||
Common Shares, no par value | |||||
ITEM 2(e) | CUSIP NUMBER: | ||||
29668H708 | |||||
ITEM 3 | STATEMENTS FILED PURSUANT TO RULES 13D-1(B) OR 13D-2(B) OR (C): | ||||
Not applicable. | |||||
Page 3 of 5
CUSIP No. 29668H708
ITEM 4 | OWNERSHIP: | ||||||||||
The information requested in this item is incorporated herein by reference to the cover page to this Schedule 13G. | |||||||||||
ITEM 5 | OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS: | ||||||||||
| X | | |||||||||||
ITEM 6 | OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON: | ||||||||||
Not applicable. | |||||||||||
ITEM 7 | IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT COMPANY: | ||||||||||
Not applicable. | |||||||||||
ITEM 8 | IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP: | ||||
Not applicable. | |||||
ITEM 9 | NOTICE OF DISSOLUTION OF GROUP: | ||||
Not applicable. | |||||
ITEM 10 | CERTIFICATION: | ||||
By signing below the undersigned certifies that, to the best of the undersigned’s knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the Issuer and were not acquired and are not held in connection with or as a participant in any transaction having such purpose or effect. | |||||
Page 4 of 5
CUSIP No. 29668H708
SIGNATURE
After reasonable inquiry and to the best of the undersigned’s knowledge and belief, the undersigned certifies that the information set forth in this statement is true, complete and correct.
Dated: February 11, 2022
PFIZER INC. | ||||||||
By: | /s/ Susan Grant | |||||||
Name: | Susan Grant | |||||||
Title: | Assistant Secretary | |||||||
Page 5 of 5